FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2293399093> ?p ?o ?g. }

• W2293399093 endingPage "574" @default.
• W2293399093 startingPage "571" @default.
• W2293399093 abstract "We report the long‐term follow‐up results of a phase II trial of IL‐1 receptor antagonist and low‐dose dexamethasone for early stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent multiple myeloma (IMM) without the need for immediate therapy. Forty seven patients were enrolled and subsequently treated with IL‐1Ra; in 25/47 low‐dose dexamethasone (20 mg weekly) was added. The primary endpoint was progression‐free survival (PFS). In the clinical trial, three patients achieved a minor response (MR) to IL‐1Ra alone; five patients a partial response (PR) and four patients an MR after addition of dexamethasone. Seven patients showed a decrease in the plasma cell labeling index (PCLI) which paralleled a decrease in the high sensitivity C‐reactive protein (hs‐CRP). The median PFS for the 47 patients was 1116 days (37.2 months). The median PFS for patients without ( n = 22) and with ( n = 25) a decrease in their baseline hs‐CRP was 326 days (11 months) vs. 3139 days (104 months) respectively ( P <0.0001). The median overall survival (OS) for the 47 patients was 3482 days (9.5 years). The median OS for patients without and with a decrease in their baseline hs‐CRP was 2885 days (7.9 years) vs. median not reached, respectively ( P = 0.001). In SMM/IMM patients at risk for progression to active myeloma, reduction in the hs‐CRP indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved PFS and OS. (Clinical Trials.gov Identifier: NCT00635154) Am. J. Hematol. 91:571–574, 2016. © 2016 Wiley Periodicals, Inc." @default.
• W2293399093 created "2016-06-24" @default.
• W2293399093 creator A5004152557 @default.
• W2293399093 creator A5028234430 @default.
• W2293399093 creator A5036150860 @default.
• W2293399093 creator A5052346975 @default.
• W2293399093 creator A5053247571 @default.
• W2293399093 creator A5060203383 @default.
• W2293399093 creator A5076611748 @default.
• W2293399093 date "2016-04-13" @default.
• W2293399093 modified "2023-09-27" @default.
• W2293399093 title "Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma" @default.
• W2293399093 cites W1515994079 @default.
• W2293399093 cites W1965607649 @default.
• W2293399093 cites W1967407728 @default.
• W2293399093 cites W1974983065 @default.
• W2293399093 cites W1979355061 @default.
• W2293399093 cites W1990617243 @default.
• W2293399093 cites W2004447523 @default.
• W2293399093 cites W2006256225 @default.
• W2293399093 cites W2007000374 @default.
• W2293399093 cites W2011764148 @default.
• W2293399093 cites W2026651855 @default.
• W2293399093 cites W2053785739 @default.
• W2293399093 cites W2062085992 @default.
• W2293399093 cites W2089608956 @default.
• W2293399093 cites W2091642454 @default.
• W2293399093 cites W2100118821 @default.
• W2293399093 cites W2113075922 @default.
• W2293399093 cites W2134215460 @default.
• W2293399093 cites W2135379188 @default.
• W2293399093 cites W2144930991 @default.
• W2293399093 cites W2158946057 @default.
• W2293399093 cites W2164807675 @default.
• W2293399093 cites W2180645505 @default.
• W2293399093 cites W2197967010 @default.
• W2293399093 cites W2258341156 @default.
• W2293399093 cites W4239348763 @default.
• W2293399093 cites W2086785325 @default.
• W2293399093 doi "https://doi.org/10.1002/ajh.24352" @default.
• W2293399093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26945843" @default.
• W2293399093 hasPublicationYear "2016" @default.
• W2293399093 type Work @default.
• W2293399093 sameAs 2293399093 @default.
• W2293399093 citedByCount "67" @default.
• W2293399093 countsByYear W22933990932017 @default.
• W2293399093 countsByYear W22933990932018 @default.
• W2293399093 countsByYear W22933990932019 @default.
• W2293399093 countsByYear W22933990932020 @default.
• W2293399093 countsByYear W22933990932021 @default.
• W2293399093 countsByYear W22933990932022 @default.
• W2293399093 countsByYear W22933990932023 @default.
• W2293399093 crossrefType "journal-article" @default.
• W2293399093 hasAuthorship W2293399093A5004152557 @default.
• W2293399093 hasAuthorship W2293399093A5028234430 @default.
• W2293399093 hasAuthorship W2293399093A5036150860 @default.
• W2293399093 hasAuthorship W2293399093A5052346975 @default.
• W2293399093 hasAuthorship W2293399093A5053247571 @default.
• W2293399093 hasAuthorship W2293399093A5060203383 @default.
• W2293399093 hasAuthorship W2293399093A5076611748 @default.
• W2293399093 hasBestOaLocation W22933990931 @default.
• W2293399093 hasConcept C126322002 @default.
• W2293399093 hasConcept C141071460 @default.
• W2293399093 hasConcept C146357865 @default.
• W2293399093 hasConcept C151730666 @default.
• W2293399093 hasConcept C168563851 @default.
• W2293399093 hasConcept C203092338 @default.
• W2293399093 hasConcept C2776364478 @default.
• W2293399093 hasConcept C2776694085 @default.
• W2293399093 hasConcept C2776914184 @default.
• W2293399093 hasConcept C2780401358 @default.
• W2293399093 hasConcept C2780739268 @default.
• W2293399093 hasConcept C2781195455 @default.
• W2293399093 hasConcept C29730261 @default.
• W2293399093 hasConcept C2989005 @default.
• W2293399093 hasConcept C31760486 @default.
• W2293399093 hasConcept C71924100 @default.
• W2293399093 hasConcept C86803240 @default.
• W2293399093 hasConcept C90924648 @default.
• W2293399093 hasConceptScore W2293399093C126322002 @default.
• W2293399093 hasConceptScore W2293399093C141071460 @default.
• W2293399093 hasConceptScore W2293399093C146357865 @default.
• W2293399093 hasConceptScore W2293399093C151730666 @default.
• W2293399093 hasConceptScore W2293399093C168563851 @default.
• W2293399093 hasConceptScore W2293399093C203092338 @default.
• W2293399093 hasConceptScore W2293399093C2776364478 @default.
• W2293399093 hasConceptScore W2293399093C2776694085 @default.
• W2293399093 hasConceptScore W2293399093C2776914184 @default.
• W2293399093 hasConceptScore W2293399093C2780401358 @default.
• W2293399093 hasConceptScore W2293399093C2780739268 @default.
• W2293399093 hasConceptScore W2293399093C2781195455 @default.
• W2293399093 hasConceptScore W2293399093C29730261 @default.
• W2293399093 hasConceptScore W2293399093C2989005 @default.
• W2293399093 hasConceptScore W2293399093C31760486 @default.
• W2293399093 hasConceptScore W2293399093C71924100 @default.
• W2293399093 hasConceptScore W2293399093C86803240 @default.
• W2293399093 hasConceptScore W2293399093C90924648 @default.
• W2293399093 hasFunder F4320332161 @default.

• next